Archive \ Volume.17 2026 Issue 3

Can Artificial Intelligence Distinguish Helpful Complexity from Harmful Polypharmacy? A Critical Evidence Review

, , ,
  1. Department of AI and Polypharmacy Assessment, Faculty of Pharmacy, University of Marrakech, Marrakech, Morocco.
  2. Department of Helpful vs. Harmful Complexity, Faculty of Pharmacy, University of Fez, Fez, Morocco.

  3. Department of Clinical Pharmacy and AI Review, Faculty of Pharmacy, University of Casablanca, Casablanca, Morocco.

Abstract

Polypharmacy may represent necessary treatment for multimorbidity or expose patients to avoidable harm. Artificial intelligence is proposed to identify inappropriate medicines, predict interactions, and support deprescribing, but model accuracy does not establish whether a regimen’s complexity is beneficial or harmful. To critically examine whether current systems distinguish helpful medication complexity from harmful polypharmacy, and to identify the evidence required for that claim. A bounded critical evidence review used seven frozen Google Scholar searches, supplementary citation searching, and publisher, PubMed, and Crossref verification. Of 104 captured records, 28 duplicates were removed, 76 were screened, 45 reports were sought, 43 were assessed, and 21 reports representing 21 studies or reviews were included. Evidence was extracted by construct, target, reference standard, validation design, patient context, clinical utility, and risk of inappropriate simplification. Prediction studies, interventions, reviews, and contextual studies were appraised using appropriate domains and synthesized without pooling. Most systems predicted criteria-defined potentially inappropriate medication labels, compiled rule-based warnings, estimated interaction or hospitalization risk, or generated clinician-mediated deprescribing suggestions. Prospective systems could increase discontinuation or reduce medication burden, yet clinical-outcome findings were limited and mixed. Patient goals, prognosis, indication, time-to-benefit, and treatment burden were rarely represented directly. Proxy-label circularity, restricted external validation, and outcome disconnect limited interpretation. Current evidence supports artificial intelligence as a source of partial medication-risk signals, not as a demonstrated judge of patient-specific regimen value. Distinguishing helpful complexity from harm requires explicit benefit representation, contextual goals, counterfactual comparison, prospective evaluation, human adjudication, and safety monitoring.


Downloads: 29
Views: 67

How to cite:
Vancouver
El Idrissi F, Bennani S, Benali Y, Ben Ali A. Can Artificial Intelligence Distinguish Helpful Complexity from Harmful Polypharmacy? A Critical Evidence Review. Arch Pharm Pract. 2026;17(3):36-45. https://doi.org/10.51847/SZ1ZvPQgAj
APA
El Idrissi, F., Bennani, S., Benali, Y., & Ben Ali, A. (2026). Can Artificial Intelligence Distinguish Helpful Complexity from Harmful Polypharmacy? A Critical Evidence Review. Archives of Pharmacy Practice, 17(3), 36-45. https://doi.org/10.51847/SZ1ZvPQgAj

Download Citation
References
  1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2
  2. Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: Register-based prospective cohort study. Clin Epidemiol. 2018;10:289-98. doi:10.2147/CLEP.S153458
  3. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: A narrative review. Expert Opin Drug Saf. 2018;17(12):1185-96. doi:10.1080/14740338.2018.1546841
  4. Thompson W, McDonald EG. Polypharmacy and deprescribing in older adults. Annu Rev Med. 2024;75:113-27. doi:10.1146/annurev-med-070822-101947
  5. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. doi:10.1136/bmj.n71
  6. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467-73. doi:10.7326/M18-0850
  7. Snyder H. Literature review as a research methodology: An overview and guidelines. J Bus Res. 2019;104:333-9. doi:10.1016/j.jbusres.2019.07.039
  8. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358. doi:10.1136/bmj.j4008
  9. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-81. doi:10.1111/jgs.18372
  10. O’Mahony D, Cherubini A, Renom Guiteras A, Denkinger M, Beuscart JB, Onder G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 3. Eur Geriatr Med. 2023;14(4):625-32. doi:10.1007/s41999-023-00777-y
  11. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. doi:10.1186/s12874-018-0611-x
  12. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51-8. doi:10.7326/M18-1376
  13. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55-61. doi:10.1002/jrsm.1411
  14. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ. 2020;368. doi:10.1136/bmj.l6890
  15. Wilfling D, Hinz A, Steinhäuser J. Big data analysis techniques to address polypharmacy in patients—a scoping review. BMC Fam Pract. 2020;21(1):180. doi:10.1186/s12875-020-01247-1
  16. Mouazer A, Tsopra R, Sedki K, Letord C, Lamy JB. Decision-support systems for managing polypharmacy in the elderly: A scoping review. J Biomed Inform. 2022;130:104074. doi:10.1016/j.jbi.2022.104074
  17. Al Meslamani AZ. Management of polypharmacy through deprescribing in older patients: A review of the role of AI tools. Expert Rev Clin Pharmacol. 2025;18(6):333-45. doi:10.1080/17512433.2025.2519648
  18. Akyon SH, Akyon FC, Yılmaz TE. Artificial intelligence-supported web application design and development for reducing polypharmacy side effects and supporting rational drug use in geriatric patients. Front Med (Lausanne). 2023;10:1029198. doi:10.3389/fmed.2023.1029198
  19. Yılmaz T, Ceyhan Ş, Akyön ŞH, Yılmaz TE. Enhancing primary care for nursing home patients with an artificial intelligence-aided rational drug use web assistant. J Clin Med. 2023;12(20):6549. doi:10.3390/jcm12206549
  20. Hu Q, Tian F, Jin Z, Lin G, Teng F, Xu T. Developing a warning model of potentially inappropriate medications in older Chinese outpatients in tertiary hospitals: A machine-learning study. J Clin Med. 2023;12(7):2619. doi:10.3390/jcm12072619
  21. McDonald EG, Wu PE, Rashidi B, Forster AJ, Huang A, Pilote L, et al. The MedSafer Study: A controlled trial of an electronic decision support tool for deprescribing in acute care. J Am Geriatr Soc. 2019;67(9):1843-50. doi:10.1111/jgs.16040
  22. McDonald EG, Wu PE, Rashidi B, Goodwin Wilson M, Bortolussi-Courval E, Atique A, et al. The MedSafer Study—electronic decision support for deprescribing in hospitalized older adults: A cluster randomized clinical trial. JAMA Intern Med. 2022;182(3):265-73. doi:10.1001/jamainternmed.2021.7429
  23. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Kripalani S, Mixon AS, et al. Deprescribing medications among older adults from end of hospitalization through postacute care: A Shed-MEDS randomized clinical trial. JAMA Intern Med. 2023;183(3):223-31. doi:10.1001/jamainternmed.2022.6545
  24. Tinetti ME, Naik AD, Dindo L, Costello DM, Esterson J, Geda M, et al. Association of patient priorities-aligned decision-making with patient outcomes and ambulatory health care burden among older adults with multiple chronic conditions: A nonrandomized clinical trial. JAMA Intern Med. 2019;179(12):1688-97. doi:10.1001/jamainternmed.2019.4235
  25. Jungo KT, Mantelli S, Rozsnyai Z, Missiou A, Gerasimovska Kitanovska B, Weltermann B, et al. General practitioners’ deprescribing decisions in older adults with polypharmacy: A case vignette study in 31 countries. BMC Geriatr. 2021;21(1):19. doi:10.1186/s12877-020-01953-6
  26. Stafford G, Villén N, Roso-Llorach A, Troncoso-Mariño A, Monteagudo M, Violán C. Combined multimorbidity and polypharmacy patterns in the elderly: A cross-sectional study in primary health care. Int J Environ Res Public Health. 2021;18(17):9216. doi:10.3390/ijerph18179216
  27. Chiu YM, Sirois C, Simard M, Gagnon ME, Talbot D. Traditional methods hold their ground against machine learning in predicting potentially inappropriate medication use in older adults. Value Health. 2024;27(10):1393-9. doi:10.1016/j.jval.2024.06.005
  28. Hu Q, Zhao M, Teng F, Lin G, Jin Z, Xu T. A model for identifying potentially inappropriate medication used in older people with dementia: A machine learning study. Int J Clin Pharm. 2024;46(4):937-46. doi:10.1007/s11096-024-01730-0
  29. Blum MR, Sallevelt BTGM, Spinewine A, O’Mahony D, Moutzouri E, Feller M, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): Cluster randomised controlled trial. BMJ. 2021;374. doi:10.1136/bmj.n1585
  30. Olender RT, Roy S, Nishtala PS. Potentially inappropriate polypharmacy is an important predictor of 30-day emergency hospitalisation in older adults: A machine learning feature validation study. Age Ageing. 2025;54(6). doi:10.1093/ageing/afaf156
  31. Vo TH, Nguyen NTK, Kha QH, Le NQK. On the road to explainable AI in drug-drug interactions prediction: A systematic review. Comput Struct Biotechnol J. 2022;20:2112-23. doi:10.1016/j.csbj.2022.04.021
  32. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics. 2018;34(13). doi:10.1093/bioinformatics/bty294
  33. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: Systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181-7. doi:10.1016/j.jamda.2019.10.022
  34. Zhou D, Chen Z, Tian F. Deprescribing interventions for older patients: A systematic review and meta-analysis. J Am Med Dir Assoc. 2023;24(11):1718-25. doi:10.1016/j.jamda.2023.07.016
  35. Hung A, Kim YH, Pavon JM. Deprescribing in older adults with polypharmacy. BMJ. 2024;385. doi:10.1136/bmj-2023-074892

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.